Burning Rock Biotech (BNR) Gross Margin (2019 - 2026)

Burning Rock Biotech's Gross Margin history runs 8 years deep, the most recent figure standing at 72.27% for Q1 2026.

• In Q1 2026, Gross Margin fell 91.0% year-over-year to 72.27%; the TTM figure through Mar 2026 stood at 74.56% (up 306.0% YoY), while the FY2025 annual figure was 74.67%, up 442.0% from the prior year.
• Gross Margin for Q1 2026 stood at 72.27%, down from 78.03% in the prior quarter.
• The five-year high for Gross Margin was 78.03% in Q4 2025, with the low at 63.13% in Q2 2022.
• The 5-year median for Gross Margin is 70.42% (2024), against an average of 70.08%.
• The sharpest annual moves came in 2022 and 2025: Gross Margin tumbled 777 bps in 2022, then jumped 707 bps in 2025.
• Burning Rock Biotech's Gross Margin stood at 71.2% in 2022, then slipped by 9 bps to 64.51% in 2023, then grew by 10 bps to 70.96% in 2024, then grew by 10 bps to 78.03% in 2025, then declined by 7 bps to 72.27% in 2026.
• Business Quant data shows BNR's Gross Margin at 72.27% in Q1 2026, 78.03% in Q4 2025, and 75.1% in Q3 2025.